改变患者游戏规则的科罗拉多大学癌症中心五大进展-动脉网

Five University of Colorado Cancer Center Advancements That Changed the Game for Patients

CISION 等信源发布 2025-06-25 02:09



可切换为仅中文







As the CU Cancer Center celebrates its 40th anniversary, here are five ways it helped to change detection and treatment of the disease.

在科罗拉多大学癌症中心庆祝其成立40周年之际，这里有五种方式展示了它如何帮助改变疾病的检测和治疗。

AURORA, Colo.

科罗拉多州奥罗拉市

，

June 24, 2025

2025年6月24日

/PRNewswire/ -- The

/PRNewswire/ --

University of Colorado

科罗拉多大学

Cancer Center

癌症中心

this year celebrates its 40th anniversary, highlighting significant advances in research and innovations that include new therapies, treatments and insights into cancer prevention.

今年庆祝其40周年，重点展示了在研究和创新方面取得的重大进展，包括新的疗法、治疗方法以及对癌症预防的深入见解。

Researcher at Gates Institute

盖茨研究所研究员

University of Colorado Cancer Center presentation

科罗拉多大学癌症中心演讲

CU Cancer Center staff

CU癌症中心工作人员

'For 40 years, the CU Cancer Center has been the cornerstone of cancer research, innovation and care in

“四十年来，CU癌症中心一直是癌症研究、创新和护理的基石，

Colorado

科罗拉多州

and the Rocky Mountain region,' says CU Anschutz Chancellor

和落基山地区，”CU安舒茨分校校长说

Donald Elliman

唐纳德·埃利曼

. 'We're not only delivering world-class care today – we're bringing new possibilities into reach and redefining the cancer treatment of the future.'

“我们不仅提供世界级的护理服务，还在实现新的可能性，重新定义未来的癌症治疗。”

The CU Cancer Center, founded in 1985, became a

科罗拉多大学癌症中心成立于1985年，成为了

National Cancer Institute-designated cancer center

国家癌症研究所指定的癌症中心

in 1988 under the leadership of its founding director,

1988年，在其创始董事的领导下，

Paul Bunn

保罗·邦

, MD. In 1997, it had the further distinction of being named one of 57 NCI Comprehensive Cancer Centers. The 'comprehensive' designation recognizes the center's strengths in basic, translational, clinical and population science research, as well as leadership and resources devoted to community outreach and engagement and cancer research training and education..

，医学博士。1997年，它还被命名为57个NCI综合癌症中心之一。 “综合”称号认可了该中心在基础、转化、临床和群体科学研发面的实力，以及致力于社区推广与参与和癌症研究培训与教育的领导力和资源。

Here are five innovations that helped make the CU Cancer Center part of the worldwide cancer conversation.

以下是帮助CU癌症中心成为全球癌症研究领域一部分的五项创新。

Multidisciplinary clinics

多学科诊所

It can take an army of specialists to treat a cancer patient, and in the early days of the CU Cancer Center, that meant multiple appointments on multiple days with specialists who may or may not have been aligned on a treatment plan.

治疗癌症患者可能需要一支由专家组成的团队，在科罗拉多大学癌症中心的早期，这意味着要在多个日子进行多次预约，而这些专家可能尚未就治疗计划达成一致。

That changed in 2012, when

2012年，当

Richard Schulick

理查德·舒里克

, MD, MBA, became chair of the

，医学博士，工商管理硕士，成为该职位的主席

CU Department of Surgery

科罗拉多大学外科系

. Schulick brought with him the concept of a multidisciplinary clinic for

。舒利克带来了多学科诊所的概念

pancreatic and biliary cancers

胰腺癌和胆道癌

in which a patient comes in for one day and is seen by multiple specialists — including surgical oncologists, medical oncologists, radiation oncologists, pathologists, dietitians and genetic counselors. They then meet that same day to develop a comprehensive treatment plan.

患者来医院就诊一天，期间会看多位专科医生，包括外科肿瘤科医生、内科肿瘤科医生、放射肿瘤科医生、病理科医生、营养师和遗传咨询师。他们当天就会面制定一项综合治疗计划。

When Schulick became director of the CU Cancer Center in 2018, he expanded the

当舒立克在2018年成为CU癌症中心的主任时，他扩展了

multidisciplinary clinics

多学科诊所

. There are now clinics for 12 types of cancer.

现在有针对12种癌症的诊所。

'It was incredible to suddenly have all these doctors come together to give me answers,' says patient

“突然间所有这些医生聚在一起给我答案，真是令人难以置信，”患者说。

Val Beck

贝克河

, who was

，他是

treated for colorectal cancer

治疗结直肠癌

at the CU Cancer Center in 2023. 'They never lied to me. They told me that my type of cancer was scary, and they said it was going to be hard. But they also said they were going to ensure I received the best treatment possible.'

在2023年CU癌症中心。‘他们从未对我撒谎。他们告诉我，我这种癌症很可怕，并且说治疗将会很艰难。但他们也表示会确保我得到尽可能最好的治疗。’

A new treatment for acute myeloid leukemia

急性髓系白血病的新疗法

Thanks in large part to early work by CU Cancer Center researchers

由于CU癌症中心研究人员的早期工作，很大程度上要感谢他们。

Craig Jordan

克雷格·乔丹

, PhD

，博士

, and

，以及

Daniel Pollyea

丹尼尔·波利娅

, MD, MS

医学博士，硕士

, patients with the

，患者们有

blood cancers

血液癌症

acute myeloid leukemia (AML) and myelodysplastic syndrome have a new treatment option that has fewer side effects and has been shown to increase longevity.

急性髓系白血病（AML）和骨髓增生异常综合征有了新的治疗选择，这种治疗副作用更少，并且已被证明可以延长寿命。

In 2020, the Food and Drug Administration granted regular approval to the drug venetoclax (Venclexta), in combination with a low-dose chemotherapy treatment, for the treatment of AML in older adults who are unfit for intensive chemotherapy.

2020年，食品药品监督管理局（FDA）正式批准药物维奈托克（Venclexta）与低剂量化疗联合使用，用于治疗无法接受高强度化疗的老年急性髓系白血病（AML）患者。

The drug works by targeting and inhibiting the Bcl-2 protein, a key component of leukemia stem cells. Of 31 evaluable patients treated with venetoclax in a 2018 clinical trial conducted by Pollyea and Jordan, 20 experienced complete remission, while eight had a complete response but with continued low blood counts..

该药物通过靶向并抑制Bcl-2蛋白（白血病干细胞的关键组成部分）起作用。在Pollyea和Jordan于2018年进行的一项临床试验中，31名可评估患者接受了维奈托克治疗，其中20人完全缓解，8人出现完全反应，但血细胞计数仍然较低。

The FDA granted the drug preliminary approval based on those clinical trials and a subsequent randomized study. Pollyea and Jordan still are researching the drug to determine how it could be even more effective, including new and upcoming studies on its effects in younger populations as well as research to tackle both upfront and post-treatment resistance..

基于这些临床试验和随后的随机研究，FDA给予了该药物初步批准。波利亚和乔丹仍在研究该药物，以确定如何使其更加有效，包括针对年轻人群体效果的新研究和即将进行的研究，以及解决治疗前和治疗后抗药性问题的研究。

'Some of our hypotheses about how we could use venetoclax weren't necessarily part of the conventional wisdom five years ago,' Pollyea says. 'It's exciting to see how many of our theories were correct, and to see how others in the hematology community have built out parts of the story that are very complementary and exciting.

“我们一些关于如何使用维奈托克的假设在五年前未必是主流观点，”波利亚说。“看到我们的许多理论被证明是正确的，真是令人兴奋，而且看到血液学界的其他人也在进一步完善这个故事的各个部分，这些内容非常互补且令人振奋。”

We're all learning from each other.'.

我们都在互相学习。

Lowering the screening age for colorectal cancer

降低结直肠癌的筛查年龄

After an alarming rise in colorectal cancer in people younger than 50, the United States Preventive Services Task Force in 2021

在50岁以下人群中结直肠癌的发病率急剧上升后，美国预防服务工作组于2021年

lowered the recommended screening age

降低了建议的筛查年龄

for the cancer from 50 to 45 for people at normal risk. One of the key figures behind the move was

对于普通风险人群，癌症筛查年龄从50岁提前到45岁。这一举措背后的关键人物之一是

Andrea Dwyer

安德烈娅·德怀尔

, program director of the

，项目总监

Colorado Cancer Screening Program

科罗拉多州癌症筛查计划

at the

在

CU Cancer Center

CU癌症中心

, who worked alongside the American Cancer Society to expand the screening population.

，他与美国癌症协会合作，扩大了筛查人群。

'The change in the guideline is going to take several years to fully catch on with people in the way we need it to, but we're already starting to see some people start their screening at age 45,' Dwyer says. 'We still have a lot of work to do on awareness of the need to start screening earlier. Colorectal cancer does happen among young adults, even teenagers, and we don't know why.'.

“指南的这一变化需要数年时间才能让人们以我们需要的方式完全接受，但我们已经看到一些人开始在45岁时进行筛查，”德怀尔说。“我们在提高对早期筛查必要性的认识方面还有很多工作要做。结直肠癌确实会发生在年轻人，甚至是青少年身上，我们不知道原因。”

Cell-based immune therapies

基于细胞的免疫疗法

Though many cancers are still effectively treated with chemotherapy and radiation, some cancers — especially blood cancers — have seen a revolution with treatments using the patient's own immune cells to attack cancer cells. The CU Cancer Center is at the forefront of this evolving science.

尽管许多癌症仍然通过化疗和放疗得到有效治疗，但某些癌症——尤其是血癌——在利用患者自身免疫细胞攻击癌细胞的治疗方法上取得了革命性进展。科罗拉多大学癌症中心处于这一不断发展的科学前沿。

Tumor-infiltrating lymphocyte therapy

肿瘤浸润淋巴细胞疗法

, for example — which is being studied by CU Cancer Center researchers including

，例如——CU癌症中心的研究人员，包括

Eduardo Davila

爱德华多·达维拉

, PhD — involves surgically removing tumor tissue from a patient's body and extracting activated T cells from the tissue. The cells are multiplied in the lab, then reinfused into the patient's body to attack tumors.

，博士——涉及从患者体内手术切除肿瘤组织，并从组织中提取激活的T细胞。这些细胞在实验室中被扩增，然后重新注入患者体内以攻击肿瘤。

The CU Cancer Center also is a national leader in chimeric antigen receptor T cell (CAR T) therapy, a powerful treatment in which a patient's immune cells are removed from their body, taken to a lab and genetically engineered to become fighter cells, then injected back into the patient, where they seek out and destroy cancer cells. .

CU癌症中心也是嵌合抗原受体T细胞（CAR T）疗法的全国领导者，这是一种强大的治疗方法，患者的免疫细胞从体内取出，带到实验室进行基因工程改造成为战斗细胞，然后重新注入患者体内，寻找并摧毁癌细胞。

One of the leaders in this effort is CU Cancer Center member

这一努力的领导者之一是CU癌症中心成员

Terry Fry

特里·弗莱

, MD, executive director of the

医学博士，执行董事

Gates Institute,

盖茨学院，

a translational research institute on the CU Anschutz Medical Campus that produces CAR T and other cellular therapies for research. Gates recently launched a clinical trial of a CAR for pediatric patients with relapsed or refractory pre B-cell acute lymphoblastic leukemia (B-ALL).

CU Anschutz医学院园区的一家转化研究机构，致力于生产CAR T和其他细胞疗法用于研究。Gates最近启动了一项针对复发或难治性前B细胞急性淋巴细胞白血病（B-ALL）儿科患者的CAR临床试验。

Elsewhere on campus,

在校园的其他地方，

先生

Eric Kohler

埃里克·科勒

, MD, PhD

，医学博士，哲学博士

, and

，以及

Catherine Danis

凯瑟琳·丹尼斯

, PhD,

，博士，

recently published research

最近发表的研究

on a next-generation CAR T therapy called ALA-CART (adjunctive LAT-activating CAR-T cells), which optimizes CAR-T cells to more effectively eliminate cancer cells, including those that have been able to hide from traditional CAR-T cells.

下一代CAR-T疗法称为ALA-CART（辅助LAT激活的CAR-T细胞），该疗法优化了CAR-T细胞，以更有效地消除癌细胞，包括那些能够逃避传统CAR-T细胞的癌细胞。

The therapy also is being studied at the

该疗法也正在被研究中

Flint Animal Cancer Cente

弗林特动物癌症中心

r at

r 在

Colorado State University

科罗拉多州立大学

, one of the CU Cancer Center's clinical partners. A trial launched in 2023 at Flint is testing the

，CU癌症中心的临床合作伙伴之一。2023年在弗林特启动的一项试验正在测试

effectiveness of CAR T treatment on naturally occurring osteosarcoma

CAR T治疗自然发生的骨肉瘤的有效性

in pet dogs.

在宠物狗中。

'These are cells that can potentially live in your body for months or even years,' says

“这些细胞有可能在你的体内存活数月甚至数年，”

Steven Dow

史蒂文·道

, DVM, PhD, 'The cells eradicate the cancerous tumor with the aim to make sure it doesn't recur.'

，兽医学博士，哲学博士，“细胞消除了癌性肿瘤，目的是确保它不会复发。”

Testing for gene mutations in lung cancer

检测肺癌的基因突变

Not all

并非所有

lung cancers

肺癌

are created equal, and researchers at the CU Cancer Center's

生而平等，科罗拉多大学癌症中心的研究人员

Thoracic Oncology Research Initiative

胸腔肿瘤研究计划

helped to pioneer the practice of testing for genetic mutations within lung cancer cells to determine which patients are likely to respond to specific medications — in some cases a single daily oral medication that allows someone diagnosed with lung cancer to enjoy a better quality of life.

帮助开创了在肺癌细胞内测试基因突变的实践，以确定哪些患者可能对特定药物产生反应——在某些情况下，仅需每日一次口服药物，就能让被诊断为肺癌的患者享受更好的生活质量。

Research into fusions and mutations by CU Cancer Center members

CU癌症中心成员对融合和突变的研究

Robert Doebele

罗伯特·多贝勒

, MD, PhD,

，医学博士，哲学博士，

Marileila Garcia

玛丽莱拉·加西亚

, PhD, and

，博士，和

Ross Camidge

罗斯·卡米奇

, MD — as well as early research in the field by

，医学博士——以及该领域早期的研究

Paul Bunn

保罗·邦

, MD, the cancer center's first director — has helped thousands of lung cancer patients worldwide.

，医学博士，该癌症中心的首任主任——已经帮助了全世界成千上万名肺癌患者。

'We're fortunate that in

“我们很幸运，在

Colorado

科罗拉多州

, we were one of the early adopters of doing routine molecular testing of our lung cancer patients, to put them into different buckets based on the mutations in their cancer,' Camidge says. 'That allowed us to say, 'OK, there are five people in front of us, and they all have lung cancer, but really, they have different subtypes of lung cancer, and they need different treatments.' When you personalize that treatment, you start to really get transformative control of the cancer.' .

“我们是早期对肺癌患者进行常规分子检测的机构之一，根据他们癌症中的基因突变将他们分类，”卡米奇说。“这让我们可以说，‘好吧，我们面前有五个人，他们都患有肺癌，但实际上，他们患有不同的肺癌亚型，需要不同的治疗。’ 当你个性化治疗时，你才开始真正获得对癌症的变革性控制。”

About the

关于

University of Colorado

科罗拉多大学

Anschutz Medical Campus

安舒茨医学校区

The

University of Colorado

科罗拉多大学

Anschutz Medical Campus is a world-class medical destination at the forefront of transformative science, medicine, education and patient care. The campus encompasses the

安舒茨医学校区是一个世界一流的医疗目的地，在变革性的科学、医学、教育和患者护理方面处于前沿。该校区涵盖

University of Colorado

科罗拉多大学

health professional schools, more than 60 centers and institutes, and two nationally ranked independent hospitals -

健康专业学校、60多个中心和研究所，以及两家全国排名的独立医院 -

UCHealth

University of Colorado

科罗拉多大学

Hospital

医院

and

和